secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2024-08-20T23:59:59+00:00
Accession:  0000950170-24-098861
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus Pharmaceuticals appoints Winston Kung to Board, replaces exiting director Chip Catlin
--------------------------------------------------------------------------------

- Avery 'Chip' Catlin resigned from Board and as Audit Chair effective Aug 15, 2024; no disagreement with company.
- Winston W. Kung, age 49, appointed to Board effective Aug 16, 2024; will serve as Audit Committee Chair.
- Kung is CFO of ArriVent BioPharma; previously COO/CFO at PMV Pharma, VP at Celgene, and roles at Citigroup and Lehman.
- Kung receives initial option grant for 5,566 shares and 5,566 RSUs; annual cash retainer $40,000 plus $20,000 for Audit Chair.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024098861/0000950170-24-098861-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024098861/crbp-20240815.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-098861

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer